Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Report 2021 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2027 (Based on 2020 COVID-19 Worldwide Spread)
Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Report 2021 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2027 (Based on 2020 COVID-19 Worldwide Spread)
Analysis of the Pharmacogenomics Technology Theranostics Companion Diagnostics (CDx) Market reveals emerging trends, consumer adoption rates, and competitive strategies among leading manufacturers worldwide.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
The Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) market is expected to grow from USD X.X million in 2021 to USD X.X million by 2027, at a CAGR of X.X% during the forecast period. The global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) market. The report focuses on well-known providers in the global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) industry, market segments, competition, and the macro environment.
Under COVID-19 Outbreak, how the Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Industry will develop is also analyzed in detail in Chapter 1.7 of the report.
In Chapter 2.4, we analyzed industry trends in the context of COVID-19.
In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.
In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.
In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.
A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.
Key players in the global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) market covered in Chapter 4:
Agilent Technologies
Leica Biosystems Nussloch GmBH
GE Healthcare
Qiagen NV
F Hoffman La Roche
Foundation Medicine
Pfizer
Thermo Fisher Scientific Inc
In Chapter 11 and 13.3, on the basis of types, the Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) market from 2016 to 2027 is primarily split into:
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
In Chapter 12 and 13.4, on the basis of applications, the Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) market from 2016 to 2027 covers:
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2016-2027) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:
North America (Covered in Chapter 6 and 13)
United States
Canada
Mexico
Europe (Covered in Chapter 7 and 13)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8 and 13)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 9 and 13)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 10 and 13)
Brazil
Argentina
Columbia
Chile
Others
Years considered for this report:
Historical Years: 2016-2020
Base Year: 2020
Estimated Year: 2021
Forecast Period: 2021-2027
Table of Content
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Regulatory Scenario by Region/Country
1.4 Market Investment Scenario Strategic
1.5 Market Analysis by Type
1.5.1 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Share by Type (2021-2027)
1.5.2 PCR
1.5.3 In-situ Hybridization
1.5.4 Immunohistochemistry
1.5.5 Sequencing
1.5.6 Others
1.6 Market by Application
1.6.1 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Share by Application (2021-2027)
1.6.2 Oncology
1.6.3 Neurological Disorders
1.6.4 Cardiovascular Disease
1.6.5 Immunological Disorders
1.6.6 Others
1.7 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Industry Development Trends under COVID-19 Outbreak
1.7.1 Global COVID-19 Status Overview
1.7.2 Influence of COVID-19 Outbreak on Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Industry Development
2. Global Market Growth Trends
2.1 Industry Trends
2.1.1 SWOT Analysis
2.1.2 Porter’s Five Forces Analysis
2.2 Potential Market and Growth Potential Analysis
2.3 Industry News and Policies by Regions
2.3.1 Industry News
2.3.2 Industry Policies
2.4 Industry Trends Under COVID-19
3 Value Chain of Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market
3.1 Value Chain Status
3.2 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Manufacturing Cost Structure Analysis
3.2.1 Production Process Analysis
3.2.2 Manufacturing Cost Structure of Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx)
3.2.3 Labor Cost of Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx)
3.2.3.1 Labor Cost of Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Under COVID-19
3.3 Sales and Marketing Model Analysis
3.4 Downstream Major Customer Analysis (by Region)
3.5 Value Chain Status Under COVID-19
4 Players Profiles
4.1 Agilent Technologies
4.1.1 Agilent Technologies Basic Information
4.1.2 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Product Profiles, Application and Specification
4.1.3 Agilent Technologies Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Performance (2016-2021)
4.1.4 Agilent Technologies Business Overview
4.2 Leica Biosystems Nussloch GmBH
4.2.1 Leica Biosystems Nussloch GmBH Basic Information
4.2.2 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Product Profiles, Application and Specification
4.2.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Performance (2016-2021)
4.2.4 Leica Biosystems Nussloch GmBH Business Overview
4.3 GE Healthcare
4.3.1 GE Healthcare Basic Information
4.3.2 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Product Profiles, Application and Specification
4.3.3 GE Healthcare Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Performance (2016-2021)
4.3.4 GE Healthcare Business Overview
4.4 Qiagen NV
4.4.1 Qiagen NV Basic Information
4.4.2 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Product Profiles, Application and Specification
4.4.3 Qiagen NV Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Performance (2016-2021)
4.4.4 Qiagen NV Business Overview
4.5 F Hoffman La Roche
4.5.1 F Hoffman La Roche Basic Information
4.5.2 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Product Profiles, Application and Specification
4.5.3 F Hoffman La Roche Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Performance (2016-2021)
4.5.4 F Hoffman La Roche Business Overview
4.6 Foundation Medicine
4.6.1 Foundation Medicine Basic Information
4.6.2 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Product Profiles, Application and Specification
4.6.3 Foundation Medicine Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Performance (2016-2021)
4.6.4 Foundation Medicine Business Overview
4.7 Pfizer
4.7.1 Pfizer Basic Information
4.7.2 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Product Profiles, Application and Specification
4.7.3 Pfizer Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Performance (2016-2021)
4.7.4 Pfizer Business Overview
4.8 Thermo Fisher Scientific Inc
4.8.1 Thermo Fisher Scientific Inc Basic Information
4.8.2 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Product Profiles, Application and Specification
4.8.3 Thermo Fisher Scientific Inc Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Performance (2016-2021)
4.8.4 Thermo Fisher Scientific Inc Business Overview
5 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Analysis by Regions
5.1 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales, Revenue and Market Share by Regions
5.1.1 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Regions (2016-2021)
5.1.2 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue by Regions (2016-2021)
5.2 North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
5.3 Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
5.4 Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
5.5 Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
5.6 South America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
6 North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Analysis by Countries
6.1 North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales, Revenue and Market Share by Countries
6.1.1 North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Countries (2016-2021)
6.1.2 North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue by Countries (2016-2021)
6.1.3 North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
6.2 United States Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
6.2.1 United States Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
6.3 Canada Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
6.4 Mexico Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
7 Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Analysis by Countries
7.1 Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales, Revenue and Market Share by Countries
7.1.1 Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Countries (2016-2021)
7.1.2 Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue by Countries (2016-2021)
7.1.3 Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
7.2 Germany Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
7.2.1 Germany Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
7.3 UK Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
7.3.1 UK Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
7.4 France Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
7.4.1 France Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
7.5 Italy Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
7.5.1 Italy Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
7.6 Spain Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
7.6.1 Spain Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
7.7 Russia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
7.7.1 Russia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
8 Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Analysis by Countries
8.1 Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales, Revenue and Market Share by Countries
8.1.1 Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Countries (2016-2021)
8.1.2 Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue by Countries (2016-2021)
8.1.3 Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
8.2 China Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
8.2.1 China Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
8.3 Japan Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
8.3.1 Japan Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
8.4 South Korea Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
8.4.1 South Korea Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
8.5 Australia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
8.6 India Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
8.6.1 India Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
8.7 Southeast Asia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
8.7.1 Southeast Asia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
9 Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Analysis by Countries
9.1 Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Countries (2016-2021)
9.1.2 Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue by Countries (2016-2021)
9.1.3 Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
9.2 Saudi Arabia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
9.3 UAE Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
9.4 Egypt Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
9.5 Nigeria Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
9.6 South Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
10 South America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Analysis by Countries
10.1 South America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales, Revenue and Market Share by Countries
10.1.1 South America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Countries (2016-2021)
10.1.2 South America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue by Countries (2016-2021)
10.1.3 South America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
10.2 Brazil Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
10.2.1 Brazil Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Under COVID-19
10.3 Argentina Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
10.4 Columbia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
10.5 Chile Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
11 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Segment by Types
11.1 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales, Revenue and Market Share by Types (2016-2021)
11.1.1 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Market Share by Types (2016-2021)
11.1.2 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue and Market Share by Types (2016-2021)
11.2 PCR Sales and Price (2016-2021)
11.3 In-situ Hybridization Sales and Price (2016-2021)
11.4 Immunohistochemistry Sales and Price (2016-2021)
11.5 Sequencing Sales and Price (2016-2021)
11.6 Others Sales and Price (2016-2021)
12 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Segment by Applications
12.1 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales, Revenue and Market Share by Applications (2016-2021)
12.1.1 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Market Share by Applications (2016-2021)
12.1.2 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue and Market Share by Applications (2016-2021)
12.2 Oncology Sales, Revenue and Growth Rate (2016-2021)
12.3 Neurological Disorders Sales, Revenue and Growth Rate (2016-2021)
12.4 Cardiovascular Disease Sales, Revenue and Growth Rate (2016-2021)
12.5 Immunological Disorders Sales, Revenue and Growth Rate (2016-2021)
12.6 Others Sales, Revenue and Growth Rate (2016-2021)
13 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Forecast by Regions (2021-2027)
13.1 Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales, Revenue and Growth Rate (2021-2027)
13.2 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Forecast by Regions (2021-2027)
13.2.1 North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Forecast (2021-2027)
13.2.2 Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Forecast (2021-2027)
13.2.3 Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Forecast (2021-2027)
13.2.4 Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Forecast (2021-2027)
13.2.5 South America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Forecast (2021-2027)
13.3 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Forecast by Types (2021-2027)
13.4 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Forecast by Applications (2021-2027)
13.5 Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Forecast Under COVID-19
14 Appendix
14.1 Methodology
14.2 Research Data Source
List of Tables and Figures
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Size Growth Rate by Type (2021-2027)
Figure Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Share by Type in 2020 & 2026
Figure PCR Features
Figure In-situ Hybridization Features
Figure Immunohistochemistry Features
Figure Sequencing Features
Figure Others Features
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Size Growth by Application (2021-2027)
Figure Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Share by Application in 2020 & 2026
Figure Oncology Description
Figure Neurological Disorders Description
Figure Cardiovascular Disease Description
Figure Immunological Disorders Description
Figure Others Description
Figure Global COVID-19 Status Overview
Table Influence of COVID-19 Outbreak on Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Industry Development
Table SWOT Analysis
Figure Porter's Five Forces Analysis
Figure Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Size and Growth Rate 2016-2027
Table Industry News
Table Industry Policies
Figure Value Chain Status of Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx)
Figure Production Process of Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx)
Figure Manufacturing Cost Structure of Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx)
Figure Major Company Analysis (by Business Distribution Base, by Product Type)
Table Downstream Major Customer Analysis (by Region)
Table Agilent Technologies Profile
Table Agilent Technologies Production, Value, Price, Gross Margin 2016-2021
Table Leica Biosystems Nussloch GmBH Profile
Table Leica Biosystems Nussloch GmBH Production, Value, Price, Gross Margin 2016-2021
Table GE Healthcare Profile
Table GE Healthcare Production, Value, Price, Gross Margin 2016-2021
Table Qiagen NV Profile
Table Qiagen NV Production, Value, Price, Gross Margin 2016-2021
Table F Hoffman La Roche Profile
Table F Hoffman La Roche Production, Value, Price, Gross Margin 2016-2021
Table Foundation Medicine Profile
Table Foundation Medicine Production, Value, Price, Gross Margin 2016-2021
Table Pfizer Profile
Table Pfizer Production, Value, Price, Gross Margin 2016-2021
Table Thermo Fisher Scientific Inc Profile
Table Thermo Fisher Scientific Inc Production, Value, Price, Gross Margin 2016-2021
Figure Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue ($) and Growth (2016-2021)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Regions (2016-2021)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Market Share by Regions (2016-2021)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue ($) by Regions (2016-2021)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Market Share by Regions (2016-2021)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Market Share by Regions in 2016
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Market Share by Regions in 2020
Figure North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure South America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue ($) and Growth (2016-2021)
Table North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Countries (2016-2021)
Table North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Market Share by Countries (2016-2021)
Figure North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Market Share by Countries in 2016
Figure United States Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Canada Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Mexico Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth (2016-2021)
Figure Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue ($) Growth (2016-2021)
Table Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Countries (2016-2021)
Table Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Market Share by Countries (2016-2021)
Figure Germany Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure UK Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure France Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Italy Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Spain Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Russia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue ($) and Growth (2016-2021)
Table Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Countries (2016-2021)
Table Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Market Share by Countries (2016-2021)
Figure China Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Japan Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure South Korea Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Australia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure India Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Southeast Asia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue ($) and Growth (2016-2021)
Table Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Countries (2016-2021)
Table Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Market Share by Countries (2016-2021)
Figure Saudi Arabia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure UAE Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Egypt Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Nigeria Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure South Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure South America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue ($) and Growth (2016-2021)
Figure Brazil Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Argentina Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Columbia Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Figure Chile Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2016-2021)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Types (2016-2021)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue ($) by Types (2016-2021)
Figure Global PCR Sales and Growth Rate (2016-2021)
Figure Global PCR Price (2016-2021)
Figure Global In-situ Hybridization Sales and Growth Rate (2016-2021)
Figure Global In-situ Hybridization Price (2016-2021)
Figure Global Immunohistochemistry Sales and Growth Rate (2016-2021)
Figure Global Immunohistochemistry Price (2016-2021)
Figure Global Sequencing Sales and Growth Rate (2016-2021)
Figure Global Sequencing Price (2016-2021)
Figure Global Others Sales and Growth Rate (2016-2021)
Figure Global Others Price (2016-2021)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales by Applications (2016-2021)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Share by Applications (2016-2021)
Figure Global Oncology Sales and Growth Rate (2016-2021)
Figure Global Oncology Revenue and Growth Rate (2016-2021)
Figure Global Neurological Disorders Sales and Growth Rate (2016-2021)
Figure Global Neurological Disorders Revenue and Growth Rate (2016-2021)
Figure Global Cardiovascular Disease Sales and Growth Rate (2016-2021)
Figure Global Cardiovascular Disease Revenue and Growth Rate (2016-2021)
Figure Global Immunological Disorders Sales and Growth Rate (2016-2021)
Figure Global Immunological Disorders Revenue and Growth Rate (2016-2021)
Figure Global Others Sales and Growth Rate (2016-2021)
Figure Global Others Revenue and Growth Rate (2016-2021)
Figure Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales and Growth Rate (2021-2027)
Figure Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue ($) and Growth Rate (2021-2027)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Forecast by Regions (2021-2027)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Forecast by Regions (2021-2027)
Figure North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Forecast (2021-2027)
Figure North America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Forecast (2021-2027)
Figure Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Forecast (2021-2027)
Figure Europe Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Forecast (2021-2027)
Figure Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Forecast (2021-2027)
Figure Asia-Pacific Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Forecast (2021-2027)
Figure Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Forecast (2021-2027)
Figure Middle East and Africa Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Forecast (2021-2027)
Figure South America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Forecast (2021-2027)
Figure South America Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Forecast (2021-2027)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Forecast by Types (2021-2027)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Market Share Forecast by Types (2021-2027)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Market Share Forecast by Types (2021-2027)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Sales Market Share Forecast by Applications (2021-2027)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Forecast by Applications (2021-2027)
Table Global Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Revenue Market Share Forecast by Applications (2021-2027)
Research Methodology:
Pharmacogenomics Technology Theranostics Companion Diagnostics (CDx) Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|